secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001140361-22-044592
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics prelim Q4 revenue ~$48-50M (+85% YoY); launches public stock offering
--------------------------------------------------------------------------------

- Preliminary Q4 2022 revenue $48-50M, up >85% YoY from $26.4M; full-year revenue $152-154M.
- Launches underwritten public offering of common stock; 30-day option for additional 15% of shares.
- Strategic review continues; received non-binding offers but board determined insufficient value.
- Expects positive cash flow from operations by Q1 2024; may require additional capital.
- Proceeds to accelerate commercialization, production, and plasma center buildout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/ny20006122x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer